Gaush Meditech Ltd. (HK:2407)
:2407
Want to see HK:2407 full AI Analyst Report?
2407 Stock Chart & Stats
HK$7.64
-HK$0.07(-0.81%)
At close: 4:00 PM EST
HK$7.64
-HK$0.07(-0.81%)
Day’s Range― - ―
52-Week RangeHK$4.75 - HK$9.99
Previous CloseN/A
Volume488.20K
Average Volume (3M)147.22K
Market Cap
HK$774.93M
Enterprise ValueHK$738.76M
Total Cash (Recent Filing)HK$440.94M
Total Debt (Recent Filing)HK$507.37M
Price to Earnings (P/E)11.2
Beta0.64
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.48%
Share Statistics
EPS (TTM)0.66
Shares Outstanding147,887,860
10 Day Avg. Volume84,250
30 Day Avg. Volume147,220
Financial Highlights & Ratios
PEG Ratio2.34
Price to Book (P/B)0.64
Price to Sales (P/S)0.78
P/FCF Ratio9.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.22
Revenue Forecast (FY)HK$1.72B
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetLeverage falling to ~0.30 and solid equity (~1.69B vs assets ~2.63B) materially reduces refinancing and liquidity risk versus earlier stressed capital structures. This lasting improvement supports financial flexibility for investment, dividends, or acquisition over the medium term.
Stronger Cash Generation (2025)A sharp improvement in 2025 operating cash flow and FCF (~110M) increases internal funding capacity and reduces reliance on external financing. Durable cash generation boosts the company's ability to fund capex, sustain dividends and deleverage over a multi‑quarter horizon.
Healthy Product MarginsGross margins near 46% signal strong product economics and pricing power in core device offerings. Even with compressed net margins, healthy gross margins provide a durable buffer to absorb cost increases and support long‑term operating profitability if volumes stabilize.
Bears Say
Revenue DeclineA 6.6% revenue decline in 2025 reflects weakening demand or pricing pressure in core markets. Persisting top‑line contraction reduces operating leverage, limits scalability and constrains cash flow and reinvestment capacity, making multi‑quarter recovery necessary to restore growth.
Margin Compression & Earnings VolatilityNet margin erosion from ~12% in 2023 to mid‑single digits reflects cost or pricing pressures and contributes to earnings volatility (including prior losses in 2021–2022). Persistent margin squeeze would limit free cash flow and reduce capacity to rebuild reserves or fund growth.
Inconsistent Cash ConversionIrregular cash conversion despite a stronger 2025 masks execution risk: negative FCF growth in 2024–2025 and uneven conversion reduce predictability of funds available for capex, dividends or debt reduction, increasing medium‑term financing uncertainty.
Gaush Meditech Ltd. News
2407 FAQ
What was Gaush Meditech Ltd.’s price range in the past 12 months?
Gaush Meditech Ltd. lowest stock price was HK$4.75 and its highest was HK$9.99 in the past 12 months.
What is Gaush Meditech Ltd.’s market cap?
Gaush Meditech Ltd.’s market cap is HK$774.93M.
When is Gaush Meditech Ltd.’s upcoming earnings report date?
Gaush Meditech Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 96 days.
How were Gaush Meditech Ltd.’s earnings last quarter?
Gaush Meditech Ltd. released its earnings results on Mar 26, 2026. The company reported HK$0.441 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.441.
Is Gaush Meditech Ltd. overvalued?
According to Wall Street analysts Gaush Meditech Ltd.’s price is currently Overvalued.
Does Gaush Meditech Ltd. pay dividends?
Gaush Meditech Ltd. pays a Annually dividend of HK$0.3 which represents an annual dividend yield of 3.48%. See more information on Gaush Meditech Ltd. dividends here
What is Gaush Meditech Ltd.’s EPS estimate?
Gaush Meditech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gaush Meditech Ltd. have?
Gaush Meditech Ltd. has 147,887,860 shares outstanding.
What happened to Gaush Meditech Ltd.’s price movement after its last earnings report?
Gaush Meditech Ltd. reported an EPS of HK$0.441 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.095%.
Which hedge fund is a major shareholder of Gaush Meditech Ltd.?
Currently, no hedge funds are holding shares in HK:2407
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gaush Meditech Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.77%
12-Months-Change
Fundamentals
Return on Equity
5.68%
Trailing 12-Months
Asset Growth
7.02%
Trailing 12-Months
Company Description
Gaush Meditech Ltd.
Gaush Meditech Ltd., together with its subsidiaries, researches and develops, produces, and sells ophthalmic medical devices in the People's Republic of China and internationally. The company operates through Proprietary Products, Distribution, Technical, and Others segments. Its ophthalmic medical devices are used for diagnosis, treatment, or surgeries, including vitreoretinal diseases, cataract, glaucoma, refractive surgery, ocular surface diseases, optometry, and pediatric ophthalmology. The Proprietary Products segment develops and produces surgical equipment and related supporting software, intra optical lens, and ophthalmic disease diagnosis and treatment equipment and related supporting consumables. The Distribution segment sells diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment, and related supporting consumables. The Technical segment provides warranty services, maintenance services, and after-sales services related consumables. The Others segment engages in the provision of equipment leasing and agent registration services; and licensing intellectual properties. The company sells its products directly and through distributors to public and private hospitals, and other customers. Gaush Meditech Ltd. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.
Technical Analysis
China Isotope & Radiation Corp.
―
EuroEyes International Eye Clinic Limited
―
JW (Cayman) Therapeutics Co. Ltd.
―
Broncus Holding Corp.
―
Zhaoke Ophthalmology Ltd.
―
Options Prices
Currently, No data available
---